Gavi Outlook

• Recent accomplishments
• Updates
• Looking forward

DCVMN Annual General Meeting
October 2015
VACCINE INTRODUCTION GOALS MET IN 2014

Country introductions
(Number of countries)

Pentavalent vaccine

<table>
<thead>
<tr>
<th>Year</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>62</td>
</tr>
<tr>
<td>2011</td>
<td>65</td>
</tr>
<tr>
<td>2012</td>
<td>70</td>
</tr>
<tr>
<td>2013</td>
<td>72</td>
</tr>
<tr>
<td>2014</td>
<td>73</td>
</tr>
<tr>
<td>2015</td>
<td>73*</td>
</tr>
</tbody>
</table>

Pneumococcal vaccine

<table>
<thead>
<tr>
<th>Year</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>3</td>
</tr>
<tr>
<td>2011</td>
<td>16</td>
</tr>
<tr>
<td>2012</td>
<td>24</td>
</tr>
<tr>
<td>2013</td>
<td>38</td>
</tr>
<tr>
<td>2014</td>
<td>46</td>
</tr>
<tr>
<td>2015</td>
<td>51*</td>
</tr>
</tbody>
</table>

Rotavirus vaccine

<table>
<thead>
<tr>
<th>Year</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>4</td>
</tr>
<tr>
<td>2011</td>
<td>5</td>
</tr>
<tr>
<td>2012</td>
<td>12</td>
</tr>
<tr>
<td>2013</td>
<td>18</td>
</tr>
<tr>
<td>2014</td>
<td>34</td>
</tr>
<tr>
<td>2015</td>
<td>35*</td>
</tr>
</tbody>
</table>

* As of 16 July 2015.
Source: Gavi, 2015.
VACCINE INTRODUCTIONS AND CAMPAIGNS IN 2014

* Refers to annual birth cohort (for vaccine introductions) or target population (for vaccine campaigns)

Pentavalent vaccine  Pneumococcal vaccine  Rotavirus vaccine  Measles 2nd dose vaccine  Measles campaign
Measles-rubella vaccine  HPV demonstration project  HPV national introduction  Meningitis A campaign  IPV
DCVMN IMPORTANT CONTRIBUTIONS

### Gavi procured value

<table>
<thead>
<tr>
<th>Year</th>
<th>DCVMN</th>
<th>IFPMA</th>
<th>OTHER</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>250M</td>
<td></td>
<td></td>
<td>250M</td>
</tr>
<tr>
<td>2013</td>
<td>500M</td>
<td></td>
<td></td>
<td>500M</td>
</tr>
<tr>
<td>2014</td>
<td>750M</td>
<td></td>
<td></td>
<td>750M</td>
</tr>
</tbody>
</table>

### Gavi procured volume

<table>
<thead>
<tr>
<th>Year</th>
<th>DCVMN</th>
<th>IFPMA</th>
<th>OTHER</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>100M</td>
<td></td>
<td></td>
<td>100M</td>
</tr>
<tr>
<td>2013</td>
<td>200M</td>
<td></td>
<td></td>
<td>200M</td>
</tr>
<tr>
<td>2014</td>
<td>300M</td>
<td></td>
<td></td>
<td>300M</td>
</tr>
</tbody>
</table>

Source: UNICEF Supply Division, 2014
MORE SECURE VACCINE SUPPLY

2014: 16 manufacturers* from 11 countries of production

- Netherlands 1
- Belgium 1
- France 1
- United States 2**
- Senegal 1
- Brazil 1
- Russia Federation 1
- Republic of Korea 2
- China 1
- India 4
- Indonesia 1

* Includes 14 Gavi suppliers and 2 manufacturers of prequalified Gavi vaccines.
** One US manufacturer also produces in the Netherlands.

Note: Country of production represents country of national regulatory agency responsible for vaccine lot release.

Source: UNICEF Supply Division and WHO list of pre-qualified vaccines, 2014
**UPDATE: Country groupings and eligibility in 2016**

<table>
<thead>
<tr>
<th>Low-income Threshold (US$ 1,045 GNI p.c.)</th>
<th>Eligibility Threshold (US$ 1,580 GNI p.c.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variable duration</td>
<td>Five year period</td>
</tr>
</tbody>
</table>

**Initial self-financing**

- Afghanistan Benin
- Burkina Faso
- Burundi
- Cambodia
- CAR
- Chad
- Comoros
- Congo DR
- Eritrea
- Ethiopia
- Gambia
- Guinea
- Guinea-Bissau
- Haiti
- Korea D.P.R.

**Preparatory transition phase**

- Madagascar
- Bangladesh
- Cameroon
- Cote d’Ivoire
- Djibouti
- Ghana
- Kenya
- Kyrgyz Republic
- Lao PDR
- Lesotho
- Mauritania
- Myanmar
- Nigeria
- Pakistan
- Sao Tome and Principe
- Senegal
- Solomon Islands
- Sudan (Republic of)
- Tajikistan
- Yemen
- Zambia

**Accelerated transition phase**

- Nicaragua
- Papua New Guinea (PNG)

**Fully self-financing**

- Angola
- Armenia
- Azerbaijan
- Bolivia
- Congo Rep.
- Cuba
- Georgia
- Guyana
- Indonesia
- Kiribati
- Moldova
- Timor-Leste
- Vietnam
- Uzbekistan

- Bhutan
- Honduras
- Mongolia
- Sri Lanka
- Ukraine
UPDATE: Revisions to Gavi’s co-financing policy

The Gavi Board adopted in June 2015 a revised Co-financing policy which brings two important changes:

- **Linking co-financing to prices for all countries in transition phases**

- **Development of payment plans to help countries get out of default**
SUCCESSFUL REPLENISHMENT: THE ASK FOR 2016–2020

The ask for 2016–2020

([US$ billion])

Total need: 9.5 billion

The ask: 7.5 billion

(1.5 bn x 5)

IFFIm and other assured resources: 2.0 billion

US$ 7.5 billion

additional funding needed for immunisation programmes through to 2020
Four strategic goals guide Gavi’s mission

**Vaccine goal**
Accelerate equitable uptake and coverage of vaccines

**Health systems goal**
Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems

**Financing goal**
Improve sustainability of national immunisation programmes

**Market shaping goal**
Shape markets for vaccines and other immunisation products

---

STRATEGIC GOALS 2016–2020
Introductions to peak in 2015 with IPV

Source: SDF v11. Base Unconstrained intro dates were used for all vaccines except Yellow Fever and Rota
**CLOSING THE IMMUNISATION GAP**

**Vaccine coverage in Gavi-supported countries by 2020**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Coverage by vaccine (%)</th>
<th>2000</th>
<th>by 2015</th>
<th>by 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measles-containing vaccine 1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>60%</td>
<td>79%</td>
<td>83%</td>
<td>100%</td>
</tr>
<tr>
<td>Pentavalent vaccine</td>
<td>68%</td>
<td>80%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles-containing vaccine 2&lt;sup&gt;nd&lt;/sup&gt; dose</td>
<td>52%</td>
<td>70%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yellow fever vaccine &lt;sup&gt;a&lt;/sup&gt;</td>
<td>44%</td>
<td>69%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal vaccine</td>
<td>39%</td>
<td>53%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus vaccine</td>
<td>23%</td>
<td>70%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rubella vaccine</td>
<td>17%</td>
<td>61%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV vaccine &lt;sup&gt;b&lt;/sup&gt;</td>
<td>4%</td>
<td>37%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Coverage refers to the final dose of each vaccine, unless otherwise stated.

<sup>a</sup> Target population and coverage estimates are based on 32 yellow fever-endemic Gavi-supported countries in Africa.

<sup>b</sup> Target population for HPV3 is 9-13 year old girls.

Sources: WHO/UNICEF coverage estimates and country official reported figures (MCV2 and rubella), as of July 2013. 2015 and 2020 coverage: Gavi strategic demand forecast version 9.
STRATEGIC GOALS 2016–2020

Four strategic goals guide Gavi’s mission

1. **Vaccine goal**: Accelerate equitable uptake and coverage of vaccines
2. **Health systems goal**: Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems
3. **Financing goal**: Improve sustainability of national immunisation programmes
4. **Market shaping goal**: Shape markets for vaccines and other immunisation products
Cold Chain Equipment Platform

Strengthen coverage and equity of immunisation

Equip 90,000 facilities with upgraded CCE and extend CCE to 45,000 unequipped facilities impacted by Platform, '000

Facilities impacted by Platform, '000
- Currently Equipped
- Country Plans
- Potential Impact

Promote the right technology for each facility

Help countries to choose the right technology & reduce closed vial wastage

Total cost of ownership

USD

Absorption 4,990
SDD 2,850

40%

Incentivise reliable equipment performance

Improve technology design to mitigate common failures

Cold Chain Equipment Platform
STRATEGIC GOALS 2016–2020

Four strategic goals guide Gavi’s mission

- **Vaccine goal**: Accelerate equitable uptake and coverage of vaccines
- **Health systems goal**: Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems
- **Financing goal**: Improve sustainability of national immunisation programmes
- **Market shaping goal**: Shape markets for vaccines and other immunisation products
2016–2020: THE PROJECTED PEAK OF INVESTMENTS

(US$ billion)

Gavi-funded costs (US$ billion)

2011-15: US$ 7.3 bn
2016-20: US$ 9.5 bn
2021-25: US$ 7.0 bn
2026-30: US$ 5.7 bn
STRATEGIC GOALS 2016–2020

Four strategic goals guide Gavi’s mission

**Vaccine goal**
Accelerate equitable uptake and coverage of vaccines

**Health systems goal**
Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems

**Financing goal**
Improve sustainability of national immunisation programmes

**Market shaping goal**
Shape markets for vaccines and other immunisation products
2011-2015 Supply & Procurement Strategy review and development of a revised strategy

- Review of objectives, scope
- Review of lessons learnt from strategy implementation and progress to date
- Consultations with stakeholders and partners
- Development of 2016-2020 Supply and Procurement Strategy
Considerations for a revised supply and procurement strategy

Current strategy provides strong foundation for the future

• 2011-2014 progress indicators
• Roadmaps, strategic demand forecasting and other core components to be maintained

Several factors will drive revisions in the strategy

• New directions in Gavi 4.0
  • Board-approved SG4 objectives and indicators:
    • Include other immunisation products, and
    • Innovation and healthy markets indicators
  • Coverage and equity
• Market shifts, e.g. 50% increase in # manufacturers
• Lessons learnt, e.g. needing a more explicit way of measuring trade-offs between objectives
• New opportunities to refine and strengthen tools and processes, e.g. expanding market-shaping partners
WHAT WE WILL ACHIEVE TOGETHER

2016–2020

300 million additional children immunised = >50% of total number of children immunised in the world
THANK YOU

#vaccineswork